CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation
Open Access
- 3 March 2014
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 4 (1) , 4261
Abstract
The basic leucine zipper transcription factor CCAAT/enhancer binding protein alpha (CEBPA) codes for a critical regulator during neutrophil differentiation. Aberrant expression or function of this protein contributes to the development of acute myeloid leukemia (AML). In this study, we identified two novel unrelated CEBPA target genes, the glycolytic enzyme hexokinase 3 (HK3) and the kruppel-like factor 5 (KLF5) transcription factor, by comparing gene profiles in two cohorts of CEBPA wild-type and mutant AML patients. In addition, we found CEBPA-dependent activation of HK3 and KLF5 transcription during all-trans retinoic acid (ATRA) mediated neutrophil differentiation of acute promyelocytic leukemia (APL) cells. Moreover, we observed direct regulation of HK3 by CEBPA, whereas our data suggest an indirect regulation of KLF5 by this transcription factor. Altogether, our data provide an explanation for low HK3 and KLF5 expression in particular AML subtype and establish these genes as novel CEBPA targets during neutrophil differentiation.Keywords
This publication has 29 references indexed in Scilit:
- SnapShot: Acute Myeloid LeukemiaCancer Cell, 2012
- PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cellsBlood, 2012
- The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemiaLeukemia Research, 2012
- KLFs and ATRA-induced differentiation: New pathways for exploitationLeukemia Research, 2011
- Deregulated expression of Kruppel-like factors in acute myeloid leukemiaLeukemia Research, 2011
- Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entityBlood, 2011
- C/EBPα Dysregulation in AML and ALLCritical Reviews™ in Oncogenesis, 2011
- C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutationsBlood, 2010
- Hematopoietic Stem Cell Expansion Precedes the Generation of Committed Myeloid Leukemia-Initiating Cells in C/EBPα Mutant AMLCancer Cell, 2009
- Complexity of CEBPA Dysregulation in Human Acute Myeloid LeukemiaClinical Cancer Research, 2009